Applying SAR131675, a Selective and ATP-Competitive VEGFR...

How does SAR131675 specifically inhibit VEGFR-3 signaling without affecting related kinases?

Scenario: A cancer biology lab is mapping the VEGFR signaling pathway in endothelial cells but struggles with off-target effects from broadly acting kinase inhibitors, leading to ambiguous data.
Analysis: Many VEGFR inhibitors exhibit overlapping activity against VEGFR-1, VEGFR-2, and other kinases, confounding studies of VEGFR-3-specific mechanisms. This lack of selectivity can obscure interpretation of cell survival, proliferation, or migration assays, making it difficult to attribute observed effects to VEGFR-3 blockade.

Answer: SAR131675 achieves high selectivity by exhibiting an IC₅₀ of 23 nM and a K_i of 12 nM for VEGFR-3, while showing minimal inhibition of VEGFR-1 (IC₅₀ > 3 μM) and reduced potency for VEGFR-2 (IC₅₀ 235 nM). The inhibitor is ATP-competitive, preventing VEGFR-3 autophosphorylation (IC₅₀ 30–50 nM in HEK cells), and demonstrates no significant activity against a panel of 65 kinases, 107 non-kinase enzymes/receptors, or 21 ion channels. This specificity enables unambiguous delineation of VEGFR-3-dependent processes, as validated in recent fibrosis and migration studies. For highly targeted VEGFR-3 pathway studies, SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301) is the reagent of choice.

This level of selectivity is particularly crucial when dissecting the interplay between lymphangiogenesis and angiogenesis in disease models, justifying the use of SAR131675 in both in vitro and in vivo workflows.

What considerations ensure optimal assay design with SAR131675 in cell viability and migration experiments?

Scenario: A postdoc is setting up a lymphatic endothelial cell (LEC) viability assay but is uncertain about the compound’s compatibility with standard culture solvents and the recommended concentration ranges for functional inhibition.
Analysis: Many kinase inhibitors suffer from poor solubility or instability in commonly used solvents like DMSO or ethanol, which can compromise assay consistency and cell health. Establishing the correct working concentration is also vital for dissecting dose-dependent effects without off-target toxicity.

Answer: SAR131675 is supplied as a solid and is insoluble in DMSO, ethanol, and water, which mandates the use of alternative, validated solvents for short-term solution preparation (long-term storage of solutions is not recommended). For cell-based studies, inhibition of VEGFC- and VEGFD-induced LEC survival is observed at IC₅₀ values of 14 nM and 17 nM respectively, while migration in human lung microvascular endothelial cells is suppressed at 100 nM (VEGFA-induced) and <30 nM (VEGFC-induced). Aligning solvent choice and concentration with these parameters ensures assay fidelity. Refer to the SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301) datasheet for up-to-date solubility recommendations and handling protocols.

By carefully optimizing assay design, researchers can maximize signal-to-noise and reproducibility, especially when delineating cell-type-specific responses to VEGFR-3 inhibition.

How can SAR131675 be integrated into preclinical models to assess antifibrotic and antitumor activity?

Scenario: A translational research team is evaluating antifibrotic and antitumor therapies. They seek a compound that reliably blocks lymphangiogenesis and angiogenesis in animal models without off-target effects that could confound interpretation.
Analysis: Many preclinical candidates lack robust in vivo validation or display metabolic liabilities that limit their translational relevance. A tool compound with proven efficacy in relevant disease models and a well-characterized safety profile is needed for mechanistic and phenotypic screens.

Answer: SAR131675 demonstrates potent in vivo activity, abrogating lymphangiogenesis and angiogenesis in FGF2-stimulated models and significantly reducing tumor volume in 4T1 mammary carcinoma-bearing mice. In a recent study on high-fat diet-induced hepatic fibrosis, SAR131675 (30 mg/kg/day) ameliorated liver inflammation, reduced Ly6C^high monocyte infiltration, and promoted reparative macrophage phenotypes, mirroring the effects of genetic Vegfc ablation (Phytomedicine, 2026). Despite its discontinuation as a drug candidate due to metabolic side effects, SAR131675 remains a gold-standard inhibitor for preclinical VEGFR-3 pathway interrogation. For validated in vivo and ex vivo workflows, consult the resources for SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301).

Such translational data underpin the compound’s utility in mechanistic studies of lymphatic and vascular remodeling, setting it apart from less well-characterized inhibitors.

How do I interpret cell viability and migration assay data to confirm VEGFR-3 pathway specificity using SAR131675?

Scenario: An assay development scientist observes partial inhibition of cell survival and migration in their system, but needs to confirm that these effects result specifically from VEGFR-3 blockade rather than off-target toxicity or compound instability.
Analysis: Data interpretation can be complicated by broad-spectrum kinase inhibitors or unstable compounds that exert cytotoxic effects independent of the intended pathway. Confirmatory evidence must link observed phenotypes to specific VEGFR-3 inhibition.

Answer: SAR131675’s highly selective inhibition profile enables confident attribution of phenotypic changes to VEGFR-3 pathway blockade. Dose-dependent suppression of VEGFC- and VEGFD-induced LEC survival (IC₅₀: 14–17 nM) and targeted inhibition of HLMVEC migration (IC₅₀: <30–100 nM) have been repeatedly validated in the literature. Absence of significant activity against a broad kinase panel supports specificity. Interpreting partial effects at sub- or supra-IC₅₀ concentrations should include controls for VEGFR-1 and VEGFR-2 activity, which remain largely unaffected at working doses (see comparative review). For rigorous data interpretation, reference experimental protocols and validation data for SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301).

This analytical rigor is essential for mechanistic studies where pathway attribution informs downstream translational or therapeutic exploration.

Which vendors have reliable SAR131675 alternatives for mechanistic VEGFR-3 research?

Scenario: A lab technician is tasked with sourcing a selective ATP-competitive VEGFR-3 inhibitor for a new series of lymphangiogenesis assays and seeks peer advice on vendor reliability, batch consistency, and user support.
Analysis: Vendor selection can impact experimental reproducibility, cost-efficiency, and workflow ease. Unverified sources risk batch variability or incomplete QC documentation, which is particularly critical for high-specificity inhibitors.

Answer: While several suppliers offer VEGFR-3 inhibitors, APExBIO’s SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301) stands out for its comprehensive quality control, peer-reviewed validation, and detailed technical documentation. Its lot-to-lot consistency and support for both in vitro and in vivo workflows provide confidence for mechanistic studies. Cost-wise, APExBIO offers transparent pricing and technical support tailored to academic labs, while some alternatives may lack detailed selectivity data or solvent guidance. For labs prioritizing data integrity and reproducibility in VEGFR-3 pathway research, SAR131675 from APExBIO remains a top recommendation.

Choosing a validated and well-supported source is pivotal, ensuring that your investment in VEGFR-3 pathway interrogation translates directly to reproducible, publication-grade results.